14844
post-template-default,single,single-post,postid-14844,single-format-standard,strata-core-1.1.1,strata-child-theme-ver-1.0.0,strata-theme-ver-3.4,ajax_fade,page_not_loaded,wpb-js-composer js-comp-ver-6.7.0,vc_responsive

Catalent acquires the Vaccine Manufacturing and Innovation Centre (VMIC), based at Harwell, Oxfordshire to expand its biologics capabilities

09:33 19 April in Life Sciences & Healthcare, News, Oxfordshire

Catalent, a global leader in enabling biopharma, cell, gene, and consumer health has announced the acquisition, from Vaccine Manufacturing and Innovation Centre UK Limited (VMIC Ltd.), of the biologics development and manufacturing facility, currently under construction and located at the world-renowned Harwell Science and Innovation Campus, a leading site in the U.K. for science and technology research breakthroughs and home to more than 40 life science companies.

Catalent reports that it plan to invest up to £120 million ($160 million) to complete the building of the facility and equip it with state-of-the-art capabilities for the development and manufacture of biologic therapies and vaccines. It is expected that the new facility will employ more than 400 people and support public and private organizations seeking to develop and manufacture biotherapeutics.

Paul Britton, Chief Executive of Thames Valley Chamber commented, “The acquisition highlights the appeal and strength in depth of the rich academic and biomedical science community centered at Harwell and around Oxford, part of a much wider world-class talent pool on offer to investors in the Thames Valley.  The collaboration and partner opportunities afforded by Catalent’s investment – another great addition to the region – will provide further opportunities to transform innovation into real treatments for patients across the UK”.

Mike Riley, President of Catalent Biotherapeutics, stated, “Our priority is to complete construction as soon as possible to be able to commence customer programs in 2022. We will then integrate its capabilities within our existing network of biologics facilities across Europe to offer a flexible range of manufacturing, technology, and development solutions for the pipeline of thousands of development programs currently underway.”

“This deal ensures the VMIC site, when completed, will stay true to the original purpose of strengthening the U.K.’s vaccine manufacturing capability by bringing innovation to the sector and getting more vaccines to the clinic,” said Professor Robin Shattock, Head of Mucosal Infection and Immunity at Imperial College London, and Chair of the Board of Directors of VMIC Ltd. “Catalent has the resources to ensure this facility can become operational and start contributing to the UK’s and Europe’s vaccines landscape at pace. I would like to recognize employees at VMIC for their passion and commitment during the pandemic and the success that their work brought to the U.K. In Catalent, we’ve found a new owner who shares the vision for what we wanted to achieve and has safeguarded the interests of the workforce.”

The new facility is located to the south of Oxford at the world-renowned Harwell Science and Innovation Campus, a leading site in the U.K. for science and technology research breakthroughs and home to more than 40 life science companies.

Read more HERE and HERE.

About Catalent:  Headquartered in New Jersey, United States, Catalent is a global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities. The business has a long-standing presence in the UK., where its workforce already exceeds 1,300 people at its four facilities focused on development and manufacturing of oral dose forms, located in Nottingham, Swindon, Haverhill, and Dartford.